Ozempic vs Other GLP-1 Medications: What the Research Actually Says

When Ozempic became a cultural phenomenon, it did something no weight-loss drug had managed in decades: it made people take pharmaceutical obesity treatment seriously. But Ozempic is just one molecule in a rapidly expanding class of medications, and if you’re trying to make an informed decision — whether you’re on a GLP-1 now, considering one, or simply trying to understand what all the noise is about — you deserve a clear-eyed look at the science, not the hype. The differences between these drugs matter enormously, and the research tells a story that’s more nuanced than most headlines suggest.

Semaglutide, the active compound in both Ozempic and Wegovy, works by mimicking glucagon-like peptide-1, a gut hormone that regulates appetite, slows gastric emptying, and enhances insulin secretion. The result is a powerful reduction in caloric intake driven by genuine neurological appetite suppression, not willpower. But the GLP-1 class now includes multiple drugs with meaningfully different mechanisms, doses, delivery methods, and clinical outcomes. Understanding those distinctions is the foundation of any intelligent conversation about which option — if any — belongs in your health strategy.

Semaglutide: The Benchmark Everyone Is Measured Against

Semaglutide has earned its status as the current gold standard in GLP-1 pharmacotherapy, and the clinical trial data backs that up. In the STEP 3 trial, once-weekly subcutaneous semaglutide at 2.4 mg produced a mean body weight reduction of 16.0% over 68 weeks, compared to just 5.7% in the placebo group — both groups receiving intensive behavioral therapy. More than 86% of participants on semaglutide lost at least 5% of their body weight, and over half achieved 15% or greater weight loss. Those are numbers that were previously associated only with bariatric surgery, not a weekly injection.

Ozempic is semaglutide at 0.5 mg, 1 mg, or 2 mg weekly — approved for type 2 diabetes management and carrying cardiovascular outcome data that Wegovy (semaglutide 2.4 mg) does not yet fully replicate in its labeling. Wegovy is the same molecule at the higher 2.4 mg dose approved specifically for chronic weight management. In practice, many physicians prescribe Ozempic off-label for weight loss, and many patients end up on a dose trajectory that mimics the Wegovy protocol. The distinction is largely regulatory and commercial rather than chemical. What matters clinically is the dose, and higher doses of semaglutide consistently produce greater weight loss.

The STEP 4 trial adds a critical dimension to the semaglutide story: what happens when you stop. Participants who continued semaglutide after an initial 20-week run-in lost an additional 7.9% of body weight, while those switched to placebo regained 6.9% — a divergence of nearly 15 percentage points. This finding has significant implications for how men should think about GLP-1 therapy. These are not short-term tools. They are chronic disease medications designed for long-term use, and stopping them without a plan — a solid nutrition foundation, a training habit, a genuine lifestyle shift — means most of the weight comes back. That’s not a reason to avoid them; it’s a reason to use them strategically as part of a broader framework, not as a standalone solution.

Oral semaglutide adds another dimension to this conversation. The OASIS 1 trial tested a 50 mg once-daily oral formulation and found that participants achieved a mean body weight reduction of 15.1% over 68 weeks, compared to 2.4% with placebo. That’s a remarkably close performance to the injectable version, though the oral formulation requires specific dosing conditions — taken fasted, 30 minutes before the first food or drink of the day — to achieve adequate absorption. For men who have needle aversion or travel frequently, oral semaglutide represents a genuinely viable alternative that doesn’t significantly sacrifice efficacy, though it’s not yet widely approved for weight management at the 50 mg dose in all markets.

Tirzepatide, Liraglutide, and the Rest of the Field

Tirzepatide — marketed as Mounjaro for diabetes and Zepbound for obesity — is the most significant challenger to semaglutide’s dominance. Where semaglutide is a selective GLP-1 receptor agonist, tirzepatide is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist. GIP receptors are expressed in fat tissue, and their activation appears to work synergistically with GLP-1 signaling in ways that translate to meaningfully greater weight loss. The SURMOUNT-1 trial, while not included in this article’s primary sources, showed tirzepatide producing up to 22.5% mean body weight loss at the highest dose — numbers that have genuinely shifted clinical expectations about what is achievable pharmacologically without surgery.

For men specifically, that additional GIP activity may matter beyond the scale. GIP receptors in adipose tissue play a role in fat partitioning and energy storage, and some researchers hypothesize that the dual mechanism may produce more favorable body composition changes, though head-to-head body composition data comparing tirzepatide directly to semaglutide in well-powered trials is still emerging. What’s clear is that tirzepatide’s efficacy ceiling appears higher than semaglutide’s, though both carry similar gastrointestinal side effect profiles — nausea, vomiting, diarrhea, and constipation being the most common complaints, typically concentrated during dose escalation.

Liraglutide, sold as Victoza for diabetes and Saxenda for weight management, is the older-generation GLP-1 that predates semaglutide’s dominance. It requires daily injection rather than weekly, achieves modestly lower weight loss on average (around 5–8% in major trials), and has largely been eclipsed by the newer agents in clinical preference. That said, it remains a legitimate option for patients who cannot access or afford semaglutide and tirzepatide, and its cardiovascular safety data in type 2 diabetes is robust. Exenatide, an even older twice-daily or once-weekly injectable GLP-1, occupies a similar position — clinically relevant but no longer the preferred first choice when newer options are available.

Then there’s the horizon. CagriSema — a co-formulation of semaglutide 2.4 mg with cagrilintide, a long-acting amylin analogue — represents the next evolution in combination pharmacotherapy. A phase 2 trial published in The Lancet found that CagriSema produced clinically relevant improvements in both glycemic control and body weight in adults with type 2 diabetes, outperforming either agent alone. Amylin is a pancreatic hormone that works on satiety through different neural pathways than GLP-1, and combining the two appears to produce additive effects. Phase 3 data in obesity without diabetes is anticipated, and early signals suggest CagriSema could push the weight loss ceiling even higher than tirzepatide. The principle here matters beyond the specific drug: combining complementary mechanisms rather than escalating a single pathway dose appears to be where this field is headed.

Dulaglutide (Trulicity) rounds out the major GLP-1 players. It’s a once-weekly injectable with strong cardiovascular outcome data — the REWIND trial showed meaningful cardiovascular event reduction in patients with type 2 diabetes and established or high cardiovascular risk — but its weight loss efficacy is modest compared to semaglutide and tirzepatide. For men whose primary concern is cardiovascular risk reduction rather than maximal weight loss, dulaglutide’s profile may be appropriate, particularly in the context of diabetes management. But for someone whose primary goal is substantial fat loss, it’s generally not the first-line choice.

GLP-1 Medications vs. Bariatric Surgery: Where They Actually Stand

One of the most clinically important comparisons is not between GLP-1 drugs themselves but between GLP-1 therapy and bariatric surgery — particularly for men with class II or III obesity. A 2025 cohort study published in JAMA Surgery using real-world insurance claims data addressed this directly. Metabolic bariatric surgery produced greater total weight loss (28.3%) than GLP-1 receptor agonists (10.3%) over two years, and at lower ongoing costs — $51,794 versus $63,483 total over two years, with the difference driven by sustained pharmacy costs in the GLP-1 group.

Those numbers deserve careful interpretation. The 10.3% average weight loss in the GLP-1 group reflects real-world heterogeneity — mixed drugs at mixed doses, variable adherence, and patient populations that differ from controlled trials. The surgical group achieved nearly three times the weight loss, and at lower two-year cost, challenging the narrative that GLP-1 medications are the obvious alternative to surgery for severe obesity. The authors note that these findings raise questions about whether bariatric surgery should still be considered a last resort. For men at the high end of the obesity spectrum — BMI above 40, or above 35 with serious metabolic comorbidities — that’s a conversation worth having with a bariatric surgeon, not just a primary care physician with a prescription pad.

That said, the population considerations matter. Bariatric surgery carries surgical risk, requires significant lifestyle adaptation, and is not appropriate for everyone. GLP-1 medications are reversible, adjustable, and increasingly accessible. For men with moderate obesity or those who are not surgical candidates, the pharmacological route remains a legitimate and evidence-backed path. The key insight from this research is that GLP-1 medications are genuinely powerful tools — they’re just not always the most powerful tool, and for severe cases, assuming they’re equivalent to surgery is a clinical mistake that may delay more effective intervention.

The cost argument also cuts in multiple directions. Surgery has high upfront costs but declining ongoing costs as the weight loss becomes self-sustaining through structural changes to the gastrointestinal tract. GLP-1 medications require indefinite use to maintain results — as STEP 4 demonstrated — which means the cost compounds annually. At current list prices, a year of Wegovy or Zepbound without insurance can exceed $15,000. Compounded semaglutide and tirzepatide from FDA-registered compounding pharmacies have offered lower-cost alternatives during drug shortages, though quality and regulatory status vary. If you’re paying out of pocket and considering long-term use, that financial reality is part of the decision framework.

What This Means For You

If you’re a man considering or currently using a GLP-1 medication, the most important thing the research communicates is this: the drug works best when it’s embedded in a life that doesn’t depend entirely on the drug. The STEP trials paired semaglutide with behavioral intervention for a reason. Men who use the appetite suppression window created by these medications to build genuine dietary structure, establish a consistent resistance training habit, and address the lifestyle factors that drove weight gain in the first place are the ones who maintain results — whether they continue the medication or eventually taper off.

Choosing between specific GLP-1 medications should be a conversation with a physician who knows your full metabolic picture, not a decision driven by which drug is most visible in the news cycle. Semaglutide (Wegovy, Ozempic) remains the most extensively studied option for weight management with the longest safety track record in this class. Tirzepatide (Zepbound, Mounjaro) offers a higher efficacy ceiling for men who need more aggressive intervention or who haven’t responded adequately to semaglutide. Oral semaglutide is a reasonable choice for those who prefer not to inject. Liraglutide and dulaglutide remain valid in specific clinical contexts, particularly cardiovascular risk reduction in type 2 diabetes. And for men with severe obesity, the data is becoming harder to ignore: bariatric surgery may still be the most effective long-term intervention available.

Regardless of which path you’re on — GLP-1, surgery, clean eating and heavy lifting, or some combination — the fundamentals don’t change. Protein intake adequate to preserve muscle during caloric deficit. Resistance training to maintain metabolic rate and body composition. Sleep quality that keeps hunger hormones in check. These aren’t optional additions to drug therapy; they’re the infrastructure that determines whether any intervention produces lasting results. The medications are getting better every year. The biology of sustainable fat loss hasn’t changed at all.